“This is akin to making the process for the tech transfer as efficient as you are trying to make the process to produce the actual material.” Part 2 of our “dissertation” on the mental and physical state of tech transfer in drug development and manufacturing outsourcing.
A biopharma professional is earning a degree in tech transfer. Literally. Here’s some of what he’s learned, including the four thorns in the side of those transferring drug development and manufacturing projects to CDMOs.
Biopharma start-ups and their investors have grown up. “They come in with a different mindset,” says Sesha Neervannan, Tarsus Pharmaceuticals, still enthusiastic about his own career move from bigger pharma to biotech.
Jana Spes of Ironwood Pharmaceuticals provides uniquely qualified analysis and guidance on working with CDMOs. Don’t be surprised if you come away thinking for your next hire, specialization is out, and the Spes model is in.
A McKinsey & Company report, “Why tech transfer may be critical to beating COVID-19,” indicates the typical time to tech transfer a new vaccine is 27-29 months. Over 2 years for a tech transfer? Experts say yes. But not for COVID-19.
We’ve uncovered a global trend in drug development and manufacturing outsourcing. I spoke to senior executives at four service providers to learn the trend is part antidote – and potentially a better option – to the “one-stop-shop” composite.
While the biopharmaceutical industry can only be commended for the work underway to bring the world vaccines and therapies to halt the spread and severity of COVID-19, it would be ironic if PhRMA uses the pandemic as leverage to maintain the drug supply-chain status quo.